New avenues for Parkinson's disease therapeutics: disease-modifying strategies based on the gut microbiota
Open accessThe DOI matches its Crossref record; 365 of the 366 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor symptoms in patients. Recent interest in the gut-brain axis has led to increasing research into the gut microbiota changes in PD patients and their impact on disease pathophysiology. As evidence is piling up on the effects of gut microbiota in disease development and progression, another front of action has opened up in relation to the potential usage of microbiota-based therapeutic strategies in treating gastrointestinal alterations and possibly also motor symptoms in PD. This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It appears that the Parkinson's disease-related gut dysbiosis is associated with the imbalance of SCFAs-producing bacteria (Prevotellaceae, Faecalibacterium, and Ruminococcaceae), bacteria that participate in lipid metabolism (e.g., Christensenellaceae) and those controlling gut permeability (e.g., Verrucomicrobiaceae, Akkermansia) [418,419,445].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [445]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An important observation is that human gut microbiota metabolizes levodopa and thereby may affect its bioavailability and efficacy.”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [445]
In the citing paper
“Identification of bacteria that metabolize levodopa to dopamine (Enterococcus faecalis) and dopamine to m-tyramine (Eggerthella lenta) [445]”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [445]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–365 of 365
St. Laurent, R., O’Brien, L. M., & Ahmad, S. T. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.037 · Cited by 199
Manfredsson, F. P., Luk, K. C., Benskey, M. J., Gezer, A., Garcia, J., Kuhn, N. C., Sandoval, I. M., Patterson, J. R., O'Mara, A., Yonkers, R., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.008 · Cited by 199
Park, J., Wang, Q., Wu, Q., Mao-Draayer, Y., & Kim, C. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-45311-y · Cited by 197 · cited 1×
“Additionally, another study showed in mice that, despite the overall protective function of SCFAs, they might have the potential to regulate autoimmune CNS inflammation both positively and negatively [185].”
BackgroundProbiotic treatment reduces depressive-like behaviour in rats independently of diet
Abildgaard, A., Elfving, B., Hokland, M., Wegener, G., & Lund, S. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.02.014 · Cited by 196
The Role of LRRK2 in Neurodegeneration of Parkinson Disease
Rui, Q., Ni, H., Li, D., Gao, R., & Chen, G. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180222165418 · Cited by 196
Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease
Maraki, M. I., Yannakoulia, M., Stamelou, M., Stefanis, L., Xiromerisiou, G., Kosmidis, M. H., Dardiotis, E., Hadjigeorgiou, G. M., Sakka, P., Anastasiou, C. A., et al. (2019) · Movement Disorders · doi:10.1002/mds.27489 · Cited by 195
Deleterious Effects of Minocycline in Animal Models of Parkinson’s Disease and Huntington’s Disease
Diguet, E., Fernagut, P., Wei, X., Du, Y., Rouland, R., Gross, C., Bezard, E., & Tison, F. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03372.x · Cited by 189 · cited 1×
“demonstrated enhanced toxicity of MPTP in monkeys treated with minocycline [215].”
BackgroundEngineering Microbial Living Therapeutics: The Synthetic Biology Toolbox
Pedrolli, D. B., Ribeiro, N. V., Squizato, P. N., de Jesus, V. N., Cozetto, D. A., Tuma, R. B., Gracindo, A., Cesar, M. B., Freire, P. J. C., da Costa, A. F. M., et al. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.09.005 · Cited by 189
Fecal microbiota transplantation therapy for Parkinson's disease: A preliminary study
Xue, L.-J., Yang, X.-Z., Tong, Q., Shen, P., Ma, S.-J., Wu, S.-N., Zheng, J.-L., & Wang, H.-G. (2020) · Medicine · doi:10.1097/md.0000000000022035 · Cited by 186
Paiva, I., Pinho, R., Pavlou, M. A., Hennion, M., Wales, P., Schütz, A.-L., Rajput, A., Szegő, É. M., Kerimoglu, C., Gerhardt, E., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx114 · Cited by 185
The concept of alpha-synuclein as a prion-like protein: ten years after
Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183
Brain-to-stomach transfer of α-synuclein via vagal preganglionic projections
Ulusoy, A., Phillips, R. J., Helwig, M., Klinkenberg, M., Powley, T. L., & Di Monte, D. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1661-y · Cited by 179
Zhou, W., Bercury, K., Cummiskey, J., Luong, N., Lebin, J., & Freed, C. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.211029 · Cited by 178
Gut Microbiota Differs Between Parkinson’s Disease Patients and Healthy Controls in Northeast China
Li, C., Cui, L., Yang, Y., Miao, J., Zhao, X., Zhang, J., Cui, G., & Zhang, Y. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00171 · Cited by 178 · cited 2×
“Bacteroidetes Prevotellaceae Prevotella 3 5 [24,60,95,98,100,107,110,111]”
Role of Diet and Nutritional Supplements in Parkinson’s Disease Progression
Mischley, L. K., Lau, R. C., & Bennett, R. D. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/6405278 · Cited by 177
Does Parkinson’s disease start in the gut?
Lionnet, A., Leclair-Visonneau, L., Neunlist, M., Murayama, S., Takao, M., Adler, C. H., Derkinderen, P., & Beach, T. G. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1777-8 · Cited by 176
A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results
(2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181342f32 · Cited by 174 · cited 1×
“Moreover, they suggest that minocycline may be of concern when considering a long-term study [216,217].”
BackgroundLRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages
Härtlova, A., Herbst, S., Peltier, J., Rodgers, A., Bilkei‐Gorzo, O., Fearns, A., Dill, B. D., Lee, H., Flynn, R., Cowley, S. A., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798694 · Cited by 174
Hsieh, T.-H., Kuo, C.-W., Hsieh, K.-H., Shieh, M.-J., Peng, C.-W., Chen, Y.-C., Chang, Y.-L., Huang, Y.-Z., Chen, C.-C., Chang, P.-K., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10040206 · Cited by 174 · cited 2×
“Moreover, the administration of probiotics had neuroprotective effects on dopaminergic cells preventing them from cell death [252].”
BackgroundREM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies
St Louis, E. K., Boeve, A. R., & Boeve, B. F. (2017) · Movement Disorders · doi:10.1002/mds.27018 · Cited by 171
Boertien, J. M., Pereira, P. A. B., Aho, V. T. E., & Scheperjans, F. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191711 · Cited by 170
Grider, J. R., & Piland, B. E. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00376.2006 · Cited by 167 · cited 1×
“They have the ability to directly affect GI physiology and the intestinal barrier function, as well as to keep digestive structures in optimal condition and have a role in peristalsis [126,127].”
BackgroundSleep disturbances in Parkinson's disease
Menza, M., Dobkin, R. D., Marin, H., & Bienfait, K. (2010) · Movement Disorders · doi:10.1002/mds.22788 · Cited by 165
LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection
Liu, W., Liu, X., Li, Y., Zhao, J., Liu, Z., Hu, Z., Wang, Y., Yao, Y., Miller, A. W., Su, B., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20170014 · Cited by 165
Dopamine agonists: their role in the treatment of Parkinson's disease
BROOKS, D. J. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.6.685 · Cited by 162 · cited 1×
“The most commonly used treatments are dopamine agonists like Levodopa (L-dopa) for dopamine replacement therapy and resulting in an improvement of motor symptoms in the early stage of the disease [36].”
MethodReglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162 · cited 1×
“Since many are already approved by regulatory agencies for use in humans, the process of getting into clinical trials would be significantly accelerated [205,206].”
BackgroundTaghizadeh, M., Tamtaji, O. R., Dadgostar, E., Daneshvar Kakhaki, R., Bahmani, F., Abolhassani, J., Aarabi, M. H., Kouchaki, E., Memarzadeh, M. R., & Asemi, Z. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.03.014 · Cited by 162
Starke Belege: Parkinson könnte im Verdauungstrakt beginnen
(2017) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0043-113319 · Cited by 161
Rhee, S. H. (2014) · Intestinal Research · doi:10.5217/ir.2014.12.2.90 · Cited by 160
Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity
Ozdemir, T., Fedorec, A. J. H., Danino, T., & Barnes, C. P. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.008 · Cited by 159
Liao, J.-F., Cheng, Y.-F., You, S.-T., Kuo, W.-C., Huang, C.-W., Chiou, J.-J., Hsu, C.-C., Hsieh-Li, H.-M., Wang, S., & Tsai, Y.-C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.07.036 · Cited by 159 · cited 2×
“MPTP-induced mouse model • Neuroprotective effects on dopaminergic cells against MPTP induced toxicity: o Upregulates expression of BDNF o Decreases the expression of pro-inflammatory cytokines o Reduces glial reactivity • Improved behavioral impairment [248]”
BackgroundSynthetic Microbes As Drug Delivery Systems
Claesen, J., & Fischbach, M. A. (2015) · ACS Synthetic Biology · doi:10.1021/sb500258b · Cited by 158
Drouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., & Cicchetti, F. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu103 · Cited by 153 · cited 1×
“Evidence from human studies reporting that TLR2 and TLR4 expression is increased in blood and brain samples of PD patients [180], and from animal studies in TLR4-KO mice treated with rotenone [172], strengthen the important role that TLR4 may play in intestinal and brain inflammation.”
BackgroundIs Braak staging valid for all types of Parkinson’s disease?
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1898-9 · Cited by 151
Probiotics for Parkinson’s Disease
Gazerani, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174121 · Cited by 151 · cited 1×
“This evidence encouraged the field to test them for PD as they might be a powerful tool to modulate PD associated dysbiosis and improve GI dysfunction [63,243].”
BackgroundFecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders
Evrensel, A., & Ceylan, M. E. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.3.231 · Cited by 150
Levodopa-induced dyskinesia: Clinical features, pathophysiology, and medical management
Pandey, S., & Srivanitchapoom, P. (2017) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_239_17 · Cited by 149 · cited 1×
“Despite its extensive use, it has been associated with many side effects such as dyskinesia [257] and its efficacy varies highly across patients and across time.”
BackgroundDutta, S. K., Verma, S., Jain, V., Surapaneni, B. K., Vinayek, R., Phillips, L., & Nair, P. P. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19044 · Cited by 149 · cited 2×
“Hence, long term carefully designed clinical trials are required to obtain definite proof of the clinical efficacy of those probiotics in PD patients [23].”
BackgroundFecal Microbiota Transplantation (FMT) in Multiple Sclerosis (MS): 942
Borody, T., Leis, S., Campbell, J., Torres, M., & Nowak, A. (2011) · American Journal of Gastroenterology · doi:10.14309/00000434-201110002-00942 · Cited by 149
N-3 Polyunsaturated Fatty Acids and the Resolution of Neuroinflammation
Joffre, C., Rey, C., & Layé, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01022 · Cited by 147
Huang, B., Liu, J., Meng, T., Li, Y., He, D., Ran, X., Chen, G., Guo, W., Kan, X., Fu, S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02527 · Cited by 146
Weis, S., Schwiertz, A., Unger, M. M., Becker, A., Faßbender, K., Ratering, S., Kohl, M., Schnell, S., Schäfer, K.-H., & Egert, M. (2019) · npj Parkinson s Disease · doi:10.1038/s41531-019-0100-x · Cited by 145
Diet in Parkinson’s Disease: Critical Role for the Microbiome
Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145
Probiotics may have beneficial effects in parkinson’s disease: In vitro evidence
Magistrelli, L., Amoruso, A., Mogna, L., Graziano, T., Cantello, R., Pane, M., & Comi, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00969 · Cited by 144 · cited 5×
“Escherichia coli and Klebsiella pneumoniae inoculation • Inhibited the growth of potential pathogen bacteria [244]”
BackgroundInfluentialGut Metagenomics-Derived Genes as Potential Biomarkers of Parkinson’s Disease
Qian, Y., Yang, X., Xu, S., Huang, P., Li, B., Du, J., He, Y., Su, B., Xu, L.-M., Wang, L., et al. (2020) · Brain · doi:10.1093/brain/awaa201 · Cited by 139
Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: is there hope?
Georgescu, D., Ancusa, O., Georgescu, L., Ionita, I., & Reisz, D. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s106284 · Cited by 138
Adaptive Strategies of the Candidate Probiotic E. coli Nissle in the Mammalian Gut
Crook, N., Ferreiro, A. L., Gasparrini, A. J., Pesesky, M. W., Gibson, M. K., Wang, B., Sun, X., Condiotte, Z. J., Dobrowolski, S., Peterson, D. A., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.02.005 · Cited by 137
Impact of omega-3 fatty acids in Parkinson's disease
Bousquet, M., Calon, F., & Cicchetti, F. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.03.001 · Cited by 135
How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology
Borghammer, P. (2018) · Movement Disorders · doi:10.1002/mds.27138 · Cited by 134
The Role of Immunosenescence in Neurodegenerative Diseases
Costantini, E., D’Angelo, C., & Reale, M. (2018) · Mediators of Inflammation · doi:10.1155/2018/6039171 · Cited by 133
Nishiwaki, H., Hamaguchi, T., Ito, M., Ishida, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · mSystems · doi:10.1128/msystems.00797-20 · Cited by 133
Tibar, H., El Bayad, K., Bouhouche, A., Ait Ben Haddou, E. H., Benomar, A., Yahyaoui, M., Benazzouz, A., & Regragui, W. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00170 · Cited by 132 · cited 1×
“In the past 15 years, non-motor PD symptoms have raised a lot of attention because they can occur years before the onset of motor symptoms [16,17].”
BackgroundRajkumar, H., Kumar, M., Das, N., Kumar, S. N., Challa, H. R., & Nagpal, R. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414555004 · Cited by 128
Braak, H., & Del Tredici, K. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023630 · Cited by 127
Glucocerebrosidase Mutations in Parkinson Disease
O’Regan, G., deSouza, R.-M., Balestrino, R., & Schapira, A. H. (2017) · Journal of Parkinson's Disease · doi:10.3233/jpd-171092 · Cited by 127 · cited 1×
“Genome-wide association studies (GWAS) have identified autosomal recessive mutations in DJ-1, PINK1, PARK7, and Parkin, as well as autosomal dominant mutations in SNCA, LRRK2, and GBA [188].”
BackgroundTHE GUT MICROBIOTA AND IMMUNE SYSTEM RELATIONSHIP IN HUMAN GRAFT-VERSUS-HOST DISEASE
Laterza, L., Rizzatti, G., Gaetani, E., Chiusolo, P., & Gasbarrini, A. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.025 · Cited by 124
Autonomic disorders predicting Parkinson's disease
Palma, J.-A., & Kaufmann, H. (2014) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70024-5 · Cited by 123 · cited 1×
“However, clinical features include non-motor symptoms such as depression [9], REM-sleep behavior disorder [10,11], autonomic dysfunction [12], olfactory disruption [13], and constipation [14,15], among others.”
BackgroundGonzález-Lizárraga, F., Socías, S. B., Ávila, C. L., Torres-Bugeau, C. M., Barbosa, L. R. S., Binolfi, A., Sepúlveda-Díaz, J. E., Del-Bel, E., Fernandez, C. O., Papy-Garcia, D., et al. (2017) · Scientific Reports · doi:10.1038/srep41755 · Cited by 119 · cited 1×
“Recent in vitro studies have shown that DOX induced the reshaping of α-syn oligomers so that they did not evolve into fibrils, thus affecting αsyn ability to destabilize biological membranes, cell viability, and seeding capacity [218].”
BackgroundGut–Brain Axis and Mood Disorder
Liu, L., & Zhu, G. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00223 · Cited by 119
Hegelmaier, T., Lebbing, M., Duscha, A., Tomaske, L., Tönges, L., Holm, J. B., Bjørn Nielsen, H., Gatermann, S. G., Przuntek, H., & Haghikia, A. (2020) · Cells · doi:10.3390/cells9020376 · Cited by 118
Doxycycline restrains glia and confers neuroprotection in a 6‐OHDA Parkinson model
Lazzarini, M., Martin, S., Mitkovski, M., Vozari, R. R., Stühmer, W., & Bel, E. D. (2013) · Glia · doi:10.1002/glia.22496 · Cited by 117
Baccouri, O., Boukerb, A. M., Farhat, L. B., Zébré, A., Zimmermann, K., Domann, E., Cambronel, M., Barreau, M., Maillot, O., Rincé, I., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00881 · Cited by 117
Motor and Non-Motor Symptoms in Parkinson’s Disease: Effects on Quality of Life
Gökçal, E., Gür, V. E., Selvitop, R., Yıldız, G. B., & Asıl, T. (2016) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2016.12758 · Cited by 116
Dietary antioxidants and risk of Parkinson's disease in two population-based cohorts
Yang, F., Wolk, A., Håkansson, N., Pedersen, N. L., & Wirdefeldt, K. (2017) · Movement Disorders · doi:10.1002/mds.27120 · Cited by 116
Initiation of Parkinson’s disease from gut to brain by δ-secretase
Ahn, E. H., Kang, S. S., Liu, X., Chen, G., Zhang, Z., Chandrasekharan, B. P., Alam, A. M., Neish, A. S., Cao, X., & Ye, K. (2019) · Cell Research · doi:10.1038/s41422-019-0241-9 · Cited by 116
New Approaches to Microbiome-Based Therapies
Wong, A. C., & Levy, M. (2019) · mSystems · doi:10.1128/msystems.00122-19 · Cited by 111 · cited 1×
“On the other hand, it has been shown that alterations in gut microbiota composition and function can lead to dysbiosis, which has been linked to the etiology of multiples GI [51] and non-GI diseases such as anxiety, depression [52], autism [53], spectrum disorders [54], AD [55], and for the interest of this review, PD…”
BackgroundZhang, F., Yue, L., Fang, X., Wang, G., Li, C., Sun, X., Jia, X., Yang, J., Song, J., Zhang, Y., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.034 · Cited by 111
Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View
Filograna, R., Beltramini, M., Bubacco, L., & Bisaglia, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030102718 · Cited by 110
Intake of antioxidant vitamins and risk of Parkinson's disease
Hughes, K. C., Gao, X., Kim, I. Y., Rimm, E. B., Wang, M., Weisskopf, M. G., Schwarzschild, M. A., & Ascherio, A. (2016) · Movement Disorders · doi:10.1002/mds.26819 · Cited by 110
Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease
Robakis, D., & Fahn, S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0249-8 · Cited by 109
Miyake, Y., Fukushima, W., Tanaka, K., Sasaki, S., Kiyohara, C., Tsuboi, Y., Yamada, T., Oeda, T., Miki, T., Kawamura, N., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03088.x · Cited by 109
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
Bortolanza, M., Nascimento, G. C., Socías, S. B., Ploper, D., Chehín, R. N., Raisman‐Vozari, R., & Bel, E. A. D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1913-1 · Cited by 109 · cited 1×
“Doxycycline (DOX) is also an inexpensive antibiotic with a broad therapeutic spectrum and exceptional bioavailability [202].”
BackgroundAnti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology
Madke, B., Pradhan, S., Kabra, P., & Singh, A. (2016) · Indian Journal of Dermatology · doi:10.4103/0019-5154.190105 · Cited by 107
Role of Dietary Supplements in the Management of Parkinson’s Disease
Ciulla, M., Marinelli, L., Cacciatore, I., & Stefano, A. D. (2019) · Biomolecules · doi:10.3390/biom9070271 · Cited by 106
Lucas, P., Landete, J., Coton, M., Coton, E., & Lonvaud-Funel, A. (2003) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(03)00787-0 · Cited by 105
Benefits of Vitamins in the Treatment of Parkinson’s Disease
Zhao, X., Zhang, M., Li, C., Jiang, X., Su, Y., & Zhang, Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9426867 · Cited by 105
Lombardi, V. C., Meirleir, K. L. D., Subramanian, K., Nourani, S. M., Dagda, R. K., Delaney, S. L., & Palotás, A. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.04.004 · Cited by 101
Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation
Bi, W., Zhu, L., Wang, C., Liang, Y., Liu, J., Shi, Q., & Tao, E. (2011) · Brain Research · doi:10.1016/j.brainres.2011.04.019 · Cited by 98 · cited 1×
“One study reported that rifampicin inhibited the production of proinflammatory factors such as iNOs, IL-1β, and TNF-α by downregulating nuclear factor-kappa B (NF-kB) and MAPK pathway from microglial cells [233].”
BackgroundAhmed, S., Busetti, A., Fotiadou, P., Vincy Jose, N., Reid, S., Georgieva, M., Brown, S., Dunbar, H., Beurket-Ascencio, G., Delday, M. I., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00402 · Cited by 98
Li, F., Wang, P., Chen, Z., Sui, X., Xie, X., & Zhang, J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134297 · Cited by 97 · cited 3×
“Verrucomicrobia Verrucomicrobiaceae 8 0 [60,98,101,103,105,106,109,119]”
BackgroundEnhancing NAD+ salvage metabolism is neuroprotective in a PINK1 model of Parkinson's disease
Lehmann, S., Loh, S. H. Y., & Martins, L. M. (2016) · Biology Open · doi:10.1242/bio.022186 · Cited by 96
Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner
Shutinoski, B., Hakimi, M., Harmsen, I. E., Lunn, M., Rocha, J., Lengacher, N., Zhou, Y. Y., Khan, J., Nguyen, A., Hake-Volling, Q., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aas9292 · Cited by 96
Microbiota and the control of blood-tissue barriers
Al-Asmakh, M., & Hedin, L. (2015) · Tissue Barriers · doi:10.1080/21688370.2015.1039691 · Cited by 93
A New Face for Old Antibiotics: Tetracyclines in Treatment of Amyloidoses
Stoilova, T., Colombo, L., Forloni, G., Tagliavini, F., & Salmona, M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400161p · Cited by 93
The Therapeutic Role of Minocycline in Parkinson’s Disease
Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93 · cited 1×
“Minocycline has been proposed as a potential therapeutic agent against PD as it exerts anti-inflammatory, anti-apoptotic, and antioxidant effects [209].”
BackgroundHernando, S., Requejo, C., Herran, E., Ruiz-Ortega, J. A., Morera-Herreras, T., Lafuente, J. V., Ugedo, L., Gainza, E., Pedraz, J. L., Igartua, M., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.10.001 · Cited by 92
Xu, L., Surathu, A., Raplee, I., Chockalingam, A., Stewart, S. R., Walker, L., Sacks, L. V., Patel, V. P., Li, Z., & Rouse, R. L. (2020) · BMC Genomics · doi:10.1186/s12864-020-6665-2 · Cited by 92 · cited 1×
“However, the usage of antibiotics can alter the relative abundance of bacterial species causing the disappearance of some and the appearance and growth of new bacterial species, thus essentially leading to dysbiosis [207].”
BackgroundMediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study
Yin, W., Löf, M., Pedersen, N. L., Sandin, S., & Fang, F. (2021) · Movement Disorders · doi:10.1002/mds.28314 · Cited by 92
CONTRIBUTIONS OF HOST AND INTESTINAL MICROFLORA IN THE METABOLISM OF l-DOPA BY THE RAT
GOLDIN, B. R., PEPPERCORN, M. A., & GOLDMAN, P. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29577-5 · Cited by 91 · cited 1×
“Thus, it has been hypothesized that L-dopa can also be metabolized by the gut microbiota using an alternative metabolic pathway and potentially reducing its bioavailability and leading to side effects [261,262].”
BackgroundMori, M. A., Delattre, A. M., Carabelli, B., Pudell, C., Bortolanza, M., Staziaki, P. V., Visentainer, J. V., Montanher, P. F., Del Bel, E. A., & Ferraz, A. C. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1290928 · Cited by 89
Paramsothy, S., Paramsothy, R., Kamm, M. A., Kaakoush, N. O., Mitchell, H. M., Rubin, D. T., & Castaño‐Rodríguez, N. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)33417-0 · Cited by 87
Chotibut, T., Davis, R. W., Arnold, J. C., Frenchek, Z., Gurwara, S., Bondada, V., Geddes, J. W., & Salvatore, M. F. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8598-0 · Cited by 86 · cited 1×
“In vivo studies proved that CTX increased GLT1 expression and glutamate uptake, attenuated tyrosine hydroxilase loss in a calciumdependent manner, and attenuated locomotor behavior deficits associated with a 6-OHDAinduced lesion [223].”
BackgroundThe Gut and Parkinson’s Disease: Hype or Hope?
Scheperjans, F., Derkinderen, P., & Borghammer, P. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-181477 · Cited by 86
O’Donovan, S. M., Crowley, E. K., Brown, J. R. ‐., O’Sullivan, O., O’Leary, O. F., Timmons, S., Nolan, Y. M., Clarke, D. J., Hyland, N. P., Joyce, S. A., et al. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13726 · Cited by 86
Pierantozzi, M., Pietroiusti, A., Sancesario, G., Lunardi, G., Fedele, E., Giacomini, P., Frasca, S., Galante, A., Marciani, M. G., & Stanzione, P. (2001) · Neurological Sciences · doi:10.1007/s100720170061 · Cited by 85 · cited 1×
“Finally, lower absorption of L-dopa has been reported in PD patients infected by Helicobacter pylori [269], suggesting that eradication of Helicobacter pylori by the aid of some probiotics might be useful in these patients (Table 3).”
BackgroundCho, Y., Son, H. J., Kim, E.-M., Choi, J. H., Kim, S. T., Ji, I. J., Choi, D. H., Joh, T. H., Kim, Y. S., & Hwang, O. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9078-1 · Cited by 85 · cited 1×
“In this case, the authors propose that the effect is due to anti-apoptotic and anti-inflammatory mechanisms involving downregulation of matrix metalloproteinase (MMP)-3 [220].”
BackgroundMicrobiome changes: an indicator of Parkinson’s disease?
Haikal, C., Chen, Q.-Q., & Li, J.-Y. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0175-7 · Cited by 83
VERNIER, P., MORET, F., CALLIER, S., SNAPYAN, M., WERSINGER, C., & SIDHU, A. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.015 · Cited by 81
Potential of Prebiotic Butyrogenic Fibers in Parkinson's Disease
Cantu-Jungles, T. M., Rasmussen, H. E., & Hamaker, B. R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00663 · Cited by 81
Nagayama, H., Hamamoto, M., Ueda, M., Nito, C., Yamaguchi, H., & Katayama, Y. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000150865.21759.bc · Cited by 79
Ådén, E., Carlsson, M., Poortvliet, E., Stenlund, H., Linder, J., Edström, M., Forsgren, L., & Håglin, L. (2011) · Nutritional Neuroscience · doi:10.1179/174313211x12966635733312 · Cited by 79
Son, M. ‐., Sim, H., Son, Y. S., Jung, K. B., Lee, M. ‐., Oh, J. ‐., Chung, S. ‐., Jung, C. ‐., & Kim, J. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12396 · Cited by 78 · cited 1×
“Interestingly, an in vitro study reported that G2019S mutation in LRRK2 causes gene expression changes in intestinal epithelial cells that may result in GI impairment [192].”
BackgroundThe Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome
Harper, A., Naghibi, M., & Garcha, D. (2018) · Foods · doi:10.3390/foods7020013 · Cited by 75
The emerging role of omega-3 fatty acids as a therapeutic option in neuropsychiatric disorders
Reimers, A., & Ljung, H. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319858901 · Cited by 75
Dong, X.-L., Wang, X., Liu, F., Liu, X., Du, Z.-R., Li, R. W., Xue, C.-H., Wong, K.-H., Wong, W.-T., Zhao, Q., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.180 · Cited by 75
Perez-Pardo, P., de Jong, E. M., Broersen, L. M., van Wijk, N., Attali, A., Garssen, J., & Kraneveld, A. D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00057 · Cited by 74
Barcia, C., de Pablos, V., Bautista‐Hernández, V., Sánchez-Bahíllo, A., Bernal, I., Fernández‐Villalba, E., Martín, J., Bañón, R., Fernández-Barreiro, A., & Herrero, M. T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.05.006 · Cited by 73
Delattre, A. M., Kiss, Á., Szawka, R. E., Anselmo-Franci, J. A., Bagatini, P. B., Xavier, L. L., Rigon, P., Achaval, M., Iagher, F., de David, C., et al. (2009) · Neuroscience Research · doi:10.1016/j.neures.2009.11.006 · Cited by 71
Mazurak, N., Broelz, E., Storr, M., & Enck, P. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15071 · Cited by 71
Clostridium difficile Infection and Fecal Microbiota Transplant
Liubakka, A., & Vaughn, B. P. (2016) · AACN Advanced Critical Care · doi:10.4037/aacnacc2016703 · Cited by 71
Parkinson’s disease as a multisystem disorder
Klingelhoefer, L., & Reichmann, H. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1692-0 · Cited by 71 · cited 1×
“Epidemiological and experimental evidence suggest that environmental factors might have an important role in triggering or propagating the pathology [64,65].”
BackgroundFang, X., Zhou, X., Miao, Y., Han, Y., Wei, J., & Chen, T. (2020) · AMB Express · doi:10.1186/s13568-020-01014-6 · Cited by 70
Ceftriaxone Blocks the Polymerization of α-Synuclein and Exerts Neuroprotective Effects in Vitro
Ruzza, P., Siligardi, G., Hussain, R., Marchiani, A., Islami, M., Bubacco, L., Delogu, G., Fabbri, D., Dettori, M. A., Sechi, M., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn400149k · Cited by 70 · cited 1×
“Interestingly, an in vitro study showed that CTX binds to α-syn with good affinity and blocks its polymerization [227].”
BackgroundFuzzati-Armentero, M. T., Cerri, S., & Blandini, F. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00232 · Cited by 68
Khalighi, A. R., Khalighi, M. R., Behdani, R., Jamali, J., Khosravi, A., Kouhestani, S., Radmanesh, H., Esmaeelzadeh, S., & Khalighi, N. (2014) · PubMed Central · Cited by 67
Neuroprotective benefits of grape seed and skin extract in a mouse model of Parkinson’s disease
Ben Youssef, S., Brisson, G., Doucet-Beaupré, H., Castonguay, A.-M., Gora, C., Amri, M., & Lévesque, M. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1616435 · Cited by 64
Bisht, R., Kaur, B., Gupta, H., & Prakash, A. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.05.009 · Cited by 62 · cited 1×
“A study showed how CTX attenuated pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and IL-β in striatum region; in addition, it diminished the oxidative injury and restored the levels of endogenous antioxidant enzymes in an MPTP PD rat model [226].”
BackgroundB Vitamins and Fatty Acids: What Do They Share with Small Vessel Disease-Related Dementia?
Moretti, R., & Peinkhofer, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225797 · Cited by 62
The gut in Parkinson’s disease: Bottom‐up, top‐down, or neither?
Leclair‐Visonneau, L., Neunlist, M., Derkinderen, P., & Lebouvier, T. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13777 · Cited by 62
Broad neuroprotective profile of nicotinamide in different mouse models of MPTP‐induced parkinsonism
Anderson, D. W., Bradbury, K. A., & Schneider, J. S. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06356.x · Cited by 60
Socías, S. B., González‐Lizárraga, F., Ávila, C. L., Vera, C., Acuña, L., Sepulveda-Diaz, J. E., Bel, E. A. D., Raisman‐Vozari, R., & Chehín, R. N. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.002 · Cited by 60 · cited 1×
“Since many are already approved by regulatory agencies for use in humans, the process of getting into clinical trials would be significantly accelerated [205,206].”
BackgroundChen, Y., Zhang, S., Zeng, B., Zhao, J., Yang, M., Zhang, M., Li, Y., Ni, Q., Wu, D., & Li, Y. (2020) · Aging · doi:10.18632/aging.102872 · Cited by 59
Xu, J., Wei, C., Xu, C., Bennett, M. C., Zhang, G., Li, F., & Tao, E. (2007) · Brain Research · doi:10.1016/j.brainres.2006.12.074 · Cited by 57 · cited 1×
“Moreover, pre-treatment of PC12 cells prior to 1-Methyl4-phenyl pyridinium (MPP+) intoxication increased cell viability and prevented α-syn aggregation [230].”
BackgroundChotibut, T., Meadows, S., Kasanga, E. A., McInnis, T., Cantu, M. A., Bishop, C., & Salvatore, M. F. (2017) · Movement Disorders · doi:10.1002/mds.27077 · Cited by 56 · cited 1×
“More recently, the same group reported that a CTX regime after a 6-OHDA-induced lesion but prior to and during L-DOPA treatment reduced dyskinesia severity [224].”
BackgroundZHOU, J.-C., & ZHANG, X.-W. (2019) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(19)30101-3 · Cited by 56 · cited 1×
“is being considered a good probiotic [137,138], the maintenance of steady state levels of Akkermansia may be a pre-requisite for gut homeostasis.”
BackgroundChanges of Colonic Bacterial Composition in Parkinson’s Disease and Other Neurodegenerative DiseasesPreprint
Gerhardt, S., & Mohajeri, M. H. (2018) · Preprints.org · doi:10.20944/preprints201804.0370.v1 · Cited by 56
Rifampicin Inhibits Rotenone-Induced Microglial Inflammation via Enhancement of Autophagy
Liang, Y., Zhou, T., Chen, Y., Lin, D., Jing, X., Peng, S., Zheng, D., Zeng, Z., Lei, M., Wu, X., et al. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.09.015 · Cited by 55 · cited 1×
“More recently, another study showed that rifampicin pre-treatment exerts neuroprotection against rotenone-induced microglia inflammation in BV2 and SH-SY5Y cells [234].”
BackgroundPaula, J. A. D., Carmuega, E., & Weill, R. (2008) · PubMed · Cited by 54
Bargossi, E., Tabanelli, G., Montanari, C., Lanciotti, R., Gatto, V., Gardini, F., & Torriani, S. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00259 · Cited by 53 · cited 17×
“In the same line, another study provided tablets, instead of using dairy products, containing two lactic bacteria, Lactobacillus acidophilus and Bifidobacterium infantis, for three months to randomly selected PD patients suffering from GI non-motor symptoms.”
BackgroundInfluentialJi, A.-L., Diao, H., Wang, X., Yang, R., Zhang, J., Luo, W., Cao, R., Cao, Z., Wang, F., & Cai, T. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.02.018 · Cited by 51
Diet and medical foods in Parkinson’s disease
Lange, K. W., NAKAMURA, Y., Chen, N., Guo, J., Kanaya, S., Lange, K. M., & Li, S. (2019) · Food Science and Human Wellness · doi:10.1016/j.fshw.2019.03.006 · Cited by 51
Can Gut Microbiota Be a Good Predictor for Parkinson’s Disease? A Machine Learning Approach
Pietrucci, D., Teofani, A., Unida, V., Cerroni, R., Biocca, S., Stefani, A., & Desideri, A. (2020) · Brain Sciences · doi:10.3390/brainsci10040242 · Cited by 51
Cilia, R., Piatti, M., Cereda, E., Bolliri, C., Caronni, S., Ferri, V., Cassani, E., Bonvegna, S., Ferrarese, C., Zecchinelli, A. L., et al. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-202297 · Cited by 51
Makaroff, L., Gunn, A., Gervasoni, C., & Richy, F. (2011) · Journal of Parkinson’s Disease · doi:10.3233/jpd-2011-001 · Cited by 50
LRRK2 in Infection: Friend or Foe?
Herbst, S., & Gutierrez, M. G. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00051 · Cited by 49
Rifampicin Attenuates the MPTP-Induced Neurotoxicity in Mouse Brain
Oida, Y., Kitaichi, K., Nakayama, H., Ito, Y., Fujimoto, Y., Shimazawa, M., Nagai, H., & Hara, H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.01.116 · Cited by 47 · cited 1×
“In vivo studies showed that rifampicin attenuated neurodegeneration of the nigrostriatal dopaminergic pathway induced by MPTP toxicity in mice through regulation of oxidative stress [235].”
BackgroundRifampicin and Parkinson’s disease
Bi, W., Zhu, L., Jing, X., Liang, Y., & Tao, E. (2012) · Neurological Sciences · doi:10.1007/s10072-012-1156-0 · Cited by 46 · cited 1×
“Rifampicin, a semi-synthetic macrocyclic antibiotic [228], has also shown to counterbalance key pathological characteristics of PD (Table 2).”
BackgroundBaldini, F., Hertel, J., Sandt, E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/691030 · Cited by 46
A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease
Mulak, A. (2018) · Movement Disorders · doi:10.1002/mds.27304 · Cited by 45 · cited 1×
“SCFAs, the major ones being butyrate, propionate, and acetate, are microbial metabolites that constitute the major products from bacterial fermentation of dietary fibers in the intestines [123,124] and are considered key candidate mediators [125].”
BackgroundPolyphenols in the management of brain disorders: Modulation of the microbiota-gut-brain axis
(2020) · Advances in Food and Nutrition Research · doi:10.1016/bs.afnr.2019.08.001 · Cited by 44
Menezes-Garcia, Z., Do Nascimento Arifa, R. D., Acúrcio, L., Brito, C. B., Gouvea, J. O., Lima, R. L., Bastos, R. W., Fialho Dias, A. C., Antunes Dourado, L. P., Bastos, L. F. S., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1765946 · Cited by 44 · cited 1×
“This family is among the most commonly overgrown bacteria in many conditions involving gut inflammation [140,141] as they are responsible for the production of the endotoxins lipopolysaccharides (LPS) [142].”
BackgroundThe Neuropathology Of Parkinson’S Disease
Forno, L. S. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0759-4_2 · Cited by 42
Severe Constipation in Parkinson's Disease and in Parkinsonisms: Prevalence and Affecting Factors
Frazzitta, G., Ferrazzoli, D., Folini, A., Palamara, G., & Maestri, R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00621 · Cited by 42 · cited 1×
“However, clinical features include non-motor symptoms such as depression [9], REM-sleep behavior disorder [10,11], autonomic dysfunction [12], olfactory disruption [13], and constipation [14,15], among others.”
BackgroundFaecal Transplantation, Pro- and Prebiotics in Parkinson’s Disease; Hope or Hype?
Van Laar, T., Boertien, J. M., & Herranz, A. H. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191802 · Cited by 42
The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherapy
Borody, T. J., Nowak, A., & Finlayson, S. (2012) · Journal of the Australasian College of Nutritional and Environmental Medicine · Cited by 40
Triglyceride Form of Docosahexaenoic Acid Mediates Neuroprotection in Experimental Parkinsonism
Gómez-Soler, M., Cordobilla, B., Morató, X., Fernández-Dueñas, V., Domingo, J. C., & Ciruela, F. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00604 · Cited by 39
Jing, X., Shi, Q., Bi, W., Zeng, Z., Liang, Y., Wu, X., Xiao, S., Liu, J., Yang, L., & Tao, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092110 · Cited by 38 · cited 1×
“A more recent study reported that rifampicin upregulated the expression of the glucose-regulated protein 78 (GRP78), a chaperone that is a hallmark of the unfolded protein response (UPR), via the PERK-eIF2α-ATF4 pathway to protect PC12 cells against rotenone-induced cytotoxicity [232].”
BackgroundMelis, M., Vascellari, S., Santoru, M. L., Oppo, V., Fabbri, M., Sarchioto, M., Murgia, D., Zibetti, M., Lopiano, L., Serra, A., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14644 · Cited by 37 · cited 1×
“Interestingly, LCIG was related with an increased relative abundance of the Enterobacteriaceae family and the genus Escherichia and Serratia compared with the L-dopa group [268], suggesting that the pharmacological treatment used influences the gut microbiota composition of PD patients.”
BackgroundHsieh, M.-H., Meng, W.-Y., Liao, W.-C., Weng, J.-C., Li, H.-H., Su, H.-L., Lin, C.-L., Hung, C.-S., & Ho, Y.-J. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.05.015 · Cited by 35
Chan, P. L. S., Nutt, J. G., & Holford, N. H. G. (2005) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-005-0039-x · Cited by 33 · cited 1×
“However, pharmacokinetics of L-dopa has been found to be highly variable between patients and its efficacy decreases over time of treatment, and sometimes it is even ineffective in some patients [260].”
BackgroundThe brain to gut pathway: a possible route of prion transmission
Lawson, V. A., Furness, J. B., Klemm, H. M., Pontell, L., Chan, E., Hill, A. F., & Chiocchetti, R. (2010) · Gut · doi:10.1136/gut.2010.222620 · Cited by 33
Kilic, �., Kılıç, E., Lingor, P., Yuluğ, B., & Bähr, M. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0867-6 · Cited by 31 · cited 1×
“Similar neuroprotective effects of rifampicin against MPP+ intoxication have been shown in dopaminergic neurons [231].”
BackgroundThe Gut Mycobiome in Parkinson’s Disease
Cirstea, M. S., Sundvick, K., Golz, E., Yu, A. C., Boutin, R. C. T., Kliger, D., Finlay, B. B., & Appel-Cresswell, S. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-202237 · Cited by 31 · cited 1×
“A recent report on the gut mycobiome in PD reported no differences in the fungi abundance between patients and controls [59], and another reported decreased total virus abundance in PD patients [60].”
BackgroundAho, V. T. E., Houser, M. C., Pereira, P. A. B., et al. (2020) · medRxiv · doi:10.1101/2020.06.15.20131011 · Cited by 28
A study on the protective role of doxycycline upon dopaminergic neuron of LPS-PD rat model rat.
Gb, Z., Yh, F., Pq, W., Jh, S., Wang, P., & Wang, S.-A. (2015) · PubMed · Cited by 21
Maekawa, T., Hitomi, S., Tsushima, H., Kawakami, F., Kawashima, R., Kubo, M., & Ichikawa, T. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4476-3 · Cited by 21 · cited 6×
“In a broader sense, it includes the neuroendocrine and neuroimmune systems, including the hypothalamic–pituitary– adrenal axis (HPA axis), sympathetic and parasympathetic arms of the autonomic nervous system (ANS), including the ENS and the vagus nerve, and the gut microbiota [57,58].”
BackgroundInfluentialTherapeutic microbes to tackle disease
Ainsworth, C. (2020) · Nature · doi:10.1038/d41586-020-00201-6 · Cited by 20
Minocycline Inhibits ICAD Degradation and the NF-ΚB Activation Induced by 6-OHDA in PC12 Cells
Jiang, B.-P., Le, L., Xu, L.-J., & Xiao, P.-G. (2014) · Brain Research · doi:10.1016/j.brainres.2014.08.001 · Cited by 19 · cited 1×
“The neuroprotective effects of minocycline were also shown in vitro against the NO-induced phosphorylation of p38 Mitogen-Activated Protein Kinase (MAPK) [210] as well as the 6-hydroxydopamine (6-OHDA)-induced cell toxicity [212].”
BackgroundCatecholaminergic neurons of mammalian brain and neuromelanin
Sukhorukova, E. G., Alekseeva, O. S., & Korzhevsky, D. E. (2014) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093014050020 · Cited by 17
Parkinson disease, levodopa and the gut microbiota—when microbiology meets pharmacology
Brüssow, H. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.14919 · Cited by 13 · cited 1×
“Thus, it has been hypothesized that L-dopa can also be metabolized by the gut microbiota using an alternative metabolic pathway and potentially reducing its bioavailability and leading to side effects [261,262].”
BackgroundImmunosenescence and the gut microbiota: The role of probiotics and prebiotics
Toward, R. E., Walton, G., & Gibson, G. R. (2012) · Nutrition and Aging · doi:10.3233/nua-130014 · Cited by 12 · cited 1×
“This contributes to the deterioration of the neuro-immune system in a process called immunosenescence [157] and is directly related with inflammaging [158,159].”
BackgroundNeuroprotective Properties of Dietary Polyphenols in Parkinson's Disease
Darvesh, A. S., McClure, M., Sadana, P., Paxos, C., Geldenhuys, W. J., Lambert, J. D., Haqqi, T. M., & Richardson, J. R. (2017) · Wiley eBooks · doi:10.1002/9781119155195.ch11 · Cited by 7
LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?
Menozzi, E., Macnaughtan, J., & Schapira, A. H. V. (2020) · Movement Disorders · doi:10.1002/mds.28347 · Cited by 5
Cansev, M., & Ulus, İ. H. (2011) · Springer eBooks · doi:10.1007/978-0-387-92271-3_32 · Cited by 3
Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism.
Merajoth, A. L., Pillai, P. S., & Iype, T. (2016) · Journal of clinical and diagnostic research : JCDR · doi:10.7860/jcdr/2016/16043.7886 · Cited by 3
Cited by
The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders
Socała, K., Doboszewska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., Poleszak, E., Fichna, J., & Wlaź, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105840 · Cited by 857
A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders
Sorboni, S. G., Moghaddam, H. S., Jafarzadeh-Esfehani, R., & Soleimanpour, S. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00338-20 · Cited by 522
Therapeutic Benefits and Dietary Restrictions of Fiber Intake: A State of the Art Review
Ioniță-Mîndrican, C.-B., Ziani, K., Mititelu, M., Oprea, E., Neacșu, S. M., Moroșan, E., Dumitrescu, D.-E., Roșca, A. C., Drăgănescu, D., & Negrei, C. (2022) · Nutrients · doi:10.3390/nu14132641 · Cited by 251
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 187
“Microbial therapy can improve the clinical manifestations of PD [43].”
BackgroundGut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., & Ling, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937555 · Cited by 177
Metadata
- Authors
- Lorente-Picón, M., & Laguna, A.
- Affiliations
- Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Corresponding author
- Laguna, Ariadna
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-03-15
- Volume
- 11
- Issue
- 3
- Pages
- 433
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC7998286
- OpenAlex
- W3139351167
- Cited by
- 69
- References
- 366
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 10 · 2023: 13 · 2022: 17 · 2021: 9
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- La Caixa Banking Foundation (LCF/BQ/PR19/11700005)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- Parkinson's disease, gut microbiota, gut-brain axis, disease-modifying therapy, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, live biotherapeutic products, antibiotics, dietary intervention, motor symptoms, neurodegeneration
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Brain, Humans, Parkinson Disease, Phylogeny, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.